Lemitias DT 25 Tablet contains Lamotrigine 25 mg, an anticonvulsant medication primarily indicated for the treatment of epilepsy and bipolar disorder. Lamotrigine acts by stabilizing neuronal membranes and inhibiting voltage-sensitive sodium channels, thereby modulating the release of excitatory neurotransmitters such as glutamate and aspartate. This mechanism helps to prevent the initiation and spread of seizure activity in the brain. Lemitias DT 25 is specifically formulated as a dispersible tablet to facilitate ease of administration, particularly in patients who have difficulty swallowing conventional tablets. It is commonly prescribed as adjunctive therapy for partial seizures, generalized seizures including tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Additionally, it is effective in the maintenance treatment of bipolar disorder to delay the occurrence of mood episodes. The dosage should be individualized based on clinical response and tolerability, with gradual titration to minimize the risk of serious adverse effects such as Stevens-Johnson syndrome. Common side effects include dizziness, headache, blurred vision, and gastrointestinal disturbances. Patients should be monitored regularly for hypersensitivity reactions and advised to report any rash or unusual symptoms promptly. Lemitias DT 25 should be used under medical supervision with consideration of potential drug interactions and contraindications.